Company Analysis: Ionis Pharmaceuticals

Company Analysis: Ionis Pharmaceuticals

  • January 2021 •
  • 44 pages •
  • Report ID: 6102716 •
  • Format: PDF
PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Ionis’s prescription pharmaceutical business will see strong growth over the forecast period.
Key themes – [1] Spinraza royalties will comprise the majority of Ionis’s revenues for the foreseeable future [2] Pharmaceutical business growth driven by launches of Tegsedi and Waylivra.

Model updates (4 November 2020)

Tegsedi forecast adjusted lower

Model updates (5 August 2020)

Tegsedi forecast adjusted lower due to sales trends
Waylivra forecast adjusted lower due to sales trends
Other revenue adjusted lower due to lower upfront licensing fees.

Model updates (6 May 2020)

No changes to forecast.

Model updates (26 February 2020)

Waylivra forecast adjusted lower due to slower-than-anticipated launch.